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Augmentation of Macular Pigment following
Implantation of Blue Light–Filtering Intraocular Lenses
at the Time of Cataract Surgery
John M. Nolan,1 Philip O’Reilly,1 James Loughman,2 Jim Stack,1 Edward Loane,1
Eithne Connolly,1 and Stephen Beatty1
PURPOSE. (Photo)-oxidative stress is believed to play a role in
the pathogenesis of age-related macular degeneration (AMD),
with the threshold for retinal damage being lowest for shortwavelength (blue) light. Macular pigment (MP), consisting of
the carotenoids lutein (L), zeaxanthin (Z) and meso-Z, has a
maximum absorption at 460 nm and protects the retina from
(photo)-oxidative injury. This study was designed to investigate
whether the blue light–filtering properties of the Alcon AcrySof Natural intraocular lens (ANIOL) implanted during cataract
surgery affects MP optical density (MPOD).
METHODS. Forty-two patients scheduled for cataract surgery
were recruited for the study. These patients all had a preoperative best corrected visual acuity rating (BCVAR) of at least 0.5
(logMAR) in the study eye. The patients were randomized to
have either the standard Alcon AcrySof three-piece acrylic
intraocular lens (AIOL) (controls) or the ANIOL implanted at
the time of cataract surgery. The spatial profile of MPOD (i.e.,
at 0.25°, 0.5°, 1.0°, and 1.75° eccentricity) was measured with
customized heterochromatic flicker photometry (cHFP) 1
week before and 1 week after surgery, and at 3, 6, and 12
months after surgery. Serum concentrations of L and Z were
also measured at each study visit.
RESULTS. There was a highly significant and positive correlation
between all MPODs (e.g., at 0.25°) recorded 1 week before and
after surgery in eyes with an AIOL implant (r ⫽ 0.915, P ⬍
0.01; paired samples t-test, P ⫽ 0.631) and in those ANIOL
implants (r ⫽ 0.868, P ⬍ 0.01; paired samples t-test, P ⫽
0.719). Average MPOD across the retina increased significantly
with time (after 3 months) in the ANIOL group (repeatedmeasures, general linear model, P ⬍ 0.05), but remained stable
in the AIOL group (repeated-measures, general linear model,
P ⬎ 0.05). There were no significant time or lens effects
observed for serum L over the study period (P ⬎ 0.05). There
was a significant time effect for serum Z over the study period
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(P ⬍ 0.05), but not a significant time/lens interaction (P ⬎
0.05).
CONCLUSIONS. Customized HFP can reliably measure the MPOD
spatial profile in the presence of lens opacity, and cataract
surgery does not artifactually alter MPOD readings. This study
also provides evidence that implanting an IOL that filters blue
light is associated with augmentation of MPOD in the absence
of raised serum concentrations of L and Z. However, further
and longitudinal study is needed to assess whether the observed increase in MPOD after implantation of blue-filtering
IOLs is associated with reduced risk of AMD development
and/or progression. (Invest Ophthalmol Vis Sci. 2009;50:
4777– 4785) DOI:10.1167/iovs.08-3277

A

ge-related macular degeneration (AMD), which damages
central vision, is the most common cause of age-related
blindness in the western world.1,2 Although the pathogenesis
of AMD remains unclear, there is a growing body of evidence
suggesting that oxidative stress is important in the pathogenesis of this condition and that cumulative short-wavelength
(blue) light damage plays a role.3–5
Macular pigment (MP), which is entirely of dietary origin,
and composed of the xanthophyll carotenoids: lutein (L), zeaxanthin (Z), and meso-Z, is thought to protect against AMD
because it absorbs short-wavelength (blue) light at a prereceptoral level and because of its antioxidant properties.6,7 The
absorption spectrum of MP peaks at 460 nm and may therefore
limit photo-oxidative damage to retinal cells.8 MP levels are
maximum within the photoreceptor axons of the foveola and
the plexiform layers of the macula.6,9 Of importance, both the
absorptive characteristics of MP and its location in the anterior
portion of individual photoreceptors enables the pigment to
attenuate the amount of blue light incident on the photoreceptor.
It has been hypothesized that cataracts provide protection
against AMD by absorbing blue light, and thus reducing photooxidative damage to the retina.10 However, this protective
effect, if any, would be restricted to certain types of lens
opacity, such as nuclear sclerosis. In contrast, however, some
studies have shown increased risk of cataract in association
with AMD, which may reflect the fact that these conditions
share antecedents (such as age).11–13 The positive association
of AMD and cataract is considered to be an effect of similar
causation and risk factors of both disorders. Although some
studies have failed to find a link between cumulative sunlight
exposure and the risk of development of AMD,14 –16 many
other studies have found a positive association between lifetime exposure to sunlight and AMD.17–20 Recently, the agerelated maculopathy and macular degeneration in elderly European populations (EUREYE) study has provided evidence of
a link between cumulative (lifetime) sunlight exposure (in the
presence of low antioxidant levels) and the risk of AMD.21
Those individuals with high cumulative lifetime exposure to
sunlight but who were in the lowest quartile for combined
antioxidant levels (especially vitamin C, zeaxanthin, vitamin E
4777
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and dietary zinc) were observed to have elevated odds ratios
for AMD.21
Cataract surgery, where the natural crystalline lens is replaced with a clear artificial intraocular lens (IOL), has been
shown to be an independent risk factor for the development or
progression of AMD.13,22 There is increased short-wavelength
light transmission to the retina after cataract surgery23,24 and
an induced short-term intraocular inflammatory response (normally dampened by topical steroid administration), and either
or both of these effects could enhance the risk of AMD progression and/or development. Indeed, ophthalmologists often
observe the progression to advanced AMD shortly after cataract surgery.25 These observations have prompted lens manufacturers to incorporate a blue-light filter into the intraocular
lens, in an attempt to attenuate photo-oxidative retinal injury
and thereby reduce the risk of AMD development and/or progression.
Alcon has been producing a yellow (blue-light filtering) IOL,
the Alcon AcrySof Natural SN60AT (ANIOL) since 2000. The
ANIOL is similar to the standard, and commonly used, AcrySof
SA60AT single-piece acrylic IOL (AIOL); however, it has a
blue-light filtering capacity. The ANIOL was one of the first
foldable IOLs to imitate the transmittance of the natural crystalline lens by combining a UV blocker with a covalently bound
chromophore that partly absorbs light in the 400- to 500-nm
spectral range. This lens is designed to simulate the light
transmission characteristics of the adult non-cataractous human crystalline lens.
This study was designed to test the effect of the standard
AIOL implant compared with the ANIOL implant on MP optical
density (MPOD) by measuring MP at baseline (soon before and
after implantation), and 3, 6, and 12 months after implantation.

METHODS
Patients and Randomization
Forty-two patients scheduled for cataract surgery at Waterford Regional Hospital (WRH), Ireland, were recruited for the study, which
was approved by the local Research Ethics Committee at WRH before
study commencement. Informed written consent was obtained from
each patient, and the experimental procedures adhered to the tenets of
the Declaration of Helsinki.
Patients with a preoperative logMAR visual acuity of less than 0.5
(the minimum required for reliable measurement of MPOD) and those
with any evidence of macular disease were not recruited. MPOD was
measured 1 week before and 1 week after surgery, and at 3, 6, and 12
months after surgery. All study visits (five in total) were performed at
the Macular Pigment Research Group’s vision science laboratory at the
Waterford Institute of Technology. The following details were recorded for each patient at baseline: lens prescription; general health
status; tobacco use; body mass index (BMI) (defined as kilograms body
weight/square meters height); ethnic background; skin color; iris
color; and dietary assessment. Dietary assessment was also performed
at the final visit. At all study visits (including baseline) the following
study outcome measures were assessed: best corrected logMAR visual
acuity; serum concentrations of L and Z (used to identify and control
for any significant dietary and/or lifestyle changes); and MPOD, including its entire spatial profile across the retina.
Surgery was performed at WRH, and all patients had a clear corneal
incision, continuous curvilinear capsulorrhexis, phacoemulsification,
and in-the-bag IOL implantation. The patients were randomized to
receive either the ANIOL or the AIOL implant at the time of surgery (in
place of the cataractous crystalline lens). The trial was conducted in a
double-blind, randomized, controlled fashion.

Dietary Assessment
Dietary assessment was performed at baseline and at the final study
visit. A crude indicator of dietary intake and bioavailability of L and Z
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was constructed according to the frequency of consumption of five
food items (dark green leafy vegetables, colored fruits and vegetables,
eggs, fish, and overall fat intake) with examples given. The frequency
of consumption was scored as follows: 0, less than once a week; 1,
once a week; 2, two to three times per week; 3, four to six times per
week; 4, once a day; 5, more than once a day. Dietary fat intake (e.g.,
fried foods, snack foods, cheese, foods cooked in butter) was assessed
due to its role in carotenoid absorption from the gut (fat intake was
scored from 1 to 5, as just outlined)26,27; fish intake was assessed due
to its high concentration of n-3 docosahexaenoic acid, which has been
shown to influence MP concentration (fish intake was also scored from
1 to 5, as just outlined).28 In this way, an aggregate score for all food
items was assigned to each person that ranged from 0 to 25. The main
purpose of assessing a person’s dietary intake was to allow for adjustment of dietary confounding factors when performing statistical comparisons with other variables (e.g., lens type and MPOD).

Serum Carotenoid Assessment
Blood samples (6 – 8 mL) were collected from all patients on the same
day as the dietary and MPOD assessment. Serum was separated from
blood by centrifugation at 5000 rpm for 10 minutes and then aliquoted
into two light-sensitive microcentrifuge tubes and stored at minus 70°C
until the time of analysis. Duplicate extractions were performed for
each serum sample. A 400-L aliquot of serum was pipetted into a
light-sensitive microcentrifuge tube (1.5 mL total capacity). Ethanol
(300 L) containing 0.25 g/L butylated hydroxytoluene (BHT) and 200
L internal standard (␣-tocopherol acetate) was added to each tube.
Heptane (500 L) was then added, and samples were vortexed vigorously for 1 minute followed by centrifugation at 2000 rpm for 5
minutes (MSC Micro Centaur; Davison & Hardy Ltd., Belfast, UK). The
resulting heptane layer was retained and transferred to a second labeled light-sensitive microcentrifuge tube, and a second heptane extraction was performed. The combined heptane layers were immediately evaporated to dryness under nitrogen. These dried samples were
reconstituted in 200 L methanol (containing 0.25 g/L BHT), and 100
L was injected for high-performance liquid chromatography (HPLC)
analysis.
We used an HPLC (1200 series; Agilent Technologies Ltd., Dublin,
Ireland) system with photodiode array detection. A 5-m analytical/
preparative 4.6 ⫻ 250-mm specialty reversed-phase column (201TP;
Vydac, Hesperia, CA) was used with an in-line guard column. The
mobile phase consisted of 97% methanol and 3% tetrahydrofuran. The
flow rate was 1 mL/min, and the total run time was 13 minutes. All
carotenoid peaks were integrated and quantified (ChemStation software; Agilent).
DSM Nutritional Products (Basel, Switzerland) provided the L and Z
standards, which were used to generate standard curves for quantification of these carotenoids. This assay was validated against the National Institute of Standards and Technology (NIST) standards before
analysis.

Macular Pigment Measurement
Apparatus. We used a macular densitometer, developed and
originally described by Wooten et al.,29 to measure MPOD, including
its spatial profile across the retina. The densitometer uses heterochromatic flicker photometry (HFP) to obtain a valid measure of MPOD at
a given retinal location.30
Procedure. The patient viewed a stimulus that alternated between a wavelength band absorbed by MP and one that was not. Test
stimuli were presented in natural view and near the center of a 6°,
2.75-cd/mm2, 470-nm circular background. The patient adjusted the
radiance of the wavelength band absorbed by MP to minimize (or
eliminate) their perception of flicker. The range of alternation rates
where flicker is not perceived is called the null zone. For the 460-nm
condition (maximum MP absorption), measurements at 0.25°, 0.5°, 1°,
and 1.75° eccentricity were obtained along the horizontal meridian of
the nasal retina (for the left eye) and temporal retina (for the right eye)
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relative to a reference location at 7° eccentricity. For the measures at
0.25° and 0.5° eccentricities, test stimuli were solid disks with those
radii, with a small black fixation dot in the center. With these stimuli,
when the flicker frequency is optimized, the edge hypothesis holds
true up to eccentricities of approximately 2°.31–33 For the 1° and 1.75°
eccentricities, centrally fixated, 20-minute wide annuli with mean radii
corresponding to those eccentricities were used. For the 7° reference
target, the test stimulus (2° diameter disc) was viewed eccentrically
using a small red light-emitting diode as a fixation target. The order of
stimulus presentation was as follows: 0.5°, 7°, 1°, 1.75°, and 0.25°.
For each stimulus condition/location, patients usually made five
judgments of null flicker. However, there were patients for whom the
initial, predicted HFP frequency value was either too high or too low.
In these situations, the experimenter adjusted the frequency of the
flickering stimulus in steps of 1 Hz, either increasing it (if the patient
could not eliminate flicker), or decreasing it (if the patient exhibited a
wide range of null flicker values). The range of null flicker was considered too wide if the patient provided values that spanned a range of
more than ⬃15% radiance units (⬃0.07 MPOD).
Customized HFP. Efforts were made in this study to optimize
and customize the method, to facilitate obtaining MP measurements
and ensure their accuracy. Similar techniques have been used in recently published studies in which MP was measured with the macular
densitometer.34,35 Primarily, it is optimal to customize the HFP task for
each patient (because of interindividual differences in flicker sensitivity) by selecting the alternation rate to achieve a narrow null zone and
a precise setting. This method has been termed customized (c)HFP.
Selecting the best flicker rate for each patient enables one to customize
the variation in flicker sensitivity, which is influenced by variables such
as age and disease.36,37 If differences among patients in flicker sensitivity are not accounted for (i.e., a fixed flicker frequency is used for
each patient), then a patient with low flicker sensitivity (i.e., low
critical flicker fusion frequency [CFF]) will most likely experience a
large null flicker zone. Although the patient may be able to complete
the task by eliminating flicker from the test target, the settings are
likely to be variable, and patients may exhibit systematic bias toward
one end of the null range, resulting in either over- or under-estimation
of MPOD. Alternatively, a patient with a high CFF may not be able to
eliminate flicker from the test target, which would make the task
difficult to complete. As described by Snodderly et al.38 the flicker
sensitivity issue can be addressed by introducing, as a preliminary test,
a CFF task using a single-wavelength band outside the absorption band
of MP. Based on an individual’s CFF, the optimal HFP flicker frequency
is estimated, which facilitates good patient performance and reduces
measurement error. An algorithm developed by Nolan and Stringham34
was used to estimate optimal HFP flicker frequencies for each retinal
locus, including the reference locus. This algorithm (based on a patient’s CFF) produced the following predicted flicker frequencies: 0.5°
⫽ CFF ⫺ 6; 7° ⫽ CFF ⫺ 12; 1° ⫽ CFF ⫺ 6; 1.75° ⫽ CFF ⫺ 7; and 0.25°
⫽ CFF ⫺ 7. Overall, the values produced by this algorithm yielded low
variability in patient settings. The optimization of HFP flicker rate is
particularly important in older patients (such as those recruited into
this trial), who often demonstrate a significant reduction in their
temporal visual sensitivity.37,39
An additional methodological consideration involves a test stimulus
configuration in which the radiances of the two alternating components are inverse-yoked. In other words, when a patient adjusts the
luminance of the blue component to a more intense level, the luminance of the green component is commensurately decreased, and vice
versa. This procedure keeps the overall brightness of the test stimulus
constant. This approach eliminates the potential distraction caused by
changes in brightness experienced by some patients when performing
the task in the unyoked setting. This aspect of cHFP is not customized
by the experimenter, but is automatically customized for each patient
because their settings reflect their own ocular absorption and retinal
sensitivity.
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MPOD values reported refer to average MPOD across the retina for
all loci measured (0.25°, 0.5°, 1°, and 1.75° of retinal eccentricity),
unless specifically stated.

Statistical Analysis
Statistical software (SPSS, ver. 15; SPSS Inc., Chicago, IL) was used for
analysis and another program was used for graphic presentations
(SigmaPlot, ver. 8.0; SPSS Inc.). All variables investigated exhibited a
typical normal distribution. Results, expressed as the mean ⫾ SD, are
presented in the text. We conducted repeated-measures analysis of
average MPOD across the retina, measured at each of five study visits
with a general linear model approach, with lens type as a betweenpatients factor. Differences between two time points, within patients,
were assessed using the paired-samples t-test. Pearson correlation coefficient analyses were conducted to investigate the relationship between bivariables. We used the 5% level of significance throughout our
analysis.

RESULTS
Baseline Findings: V1
Patients. Forty-two patients were recruited. The patients
were randomized to receive either the AIOL (n ⫽ 21) or the
ANIOL (n ⫽ 21) implant as a lens replacement in their cataract
surgery. Of the 42 patients recruited, 30 attended all study
visits (1 week before surgery, 1 week after surgery, and 3, 6,
and 12 months after surgery: V1, V2, V3, V4, and V5, respectively). One patient from the AIOL group withdrew after V1,
two after V2, and two after V4 (n ⫽ 5 withdrawals in total).
Three patients from the ANIOL group withdrew after V1, two
after V2, and two after V4 (n ⫽ 7 withdrawals in total). The
reasons for withdrawal were as follows: patient illness (nonocular); patient deceased; logistics of transport; and not interested in participating further.
Age. The mean age of the patients recruited into the study
was 73 ⫾ 11 years. The mean age of the patients recruited into
the AIOL arm was 71 ⫾ 11 years, whereas the mean age of the
patients recruited into the ANIOL arm was 74 ⫾ 11 years (P ⫽
0.370).
Sex. Twenty-five of the patients recruited into the study
were men and 17 were women. In the AIOL group, 13 of the
patients were men and 8 were women, whereas in the ANIOL
group, 12 were men and 9 were women.
Body Mass Index. The mean BMI was 27 ⫾ 5 in the entire
study group, 29 ⫾ 5 in the AIOL group, and 25 ⫾ 4 in the
ANIOL group (P ⫽ 0.017).
Diet. As described earlier, each patient was assigned a
dietary score representing his/her overall dietary intake of
foods containing the macular carotenoids. For the entire study
group, the mean diet score was 9.7 ⫾ 3.6 of a possible 25, for
the AIOL arm it was 8.8 ⫾ 3.3, and for the ANIOL arm it was
10.7 ⫾ 3.8 (P ⫽ 0.132).
Serum L and Z. The mean serum concentration of L at V1
in the entire study group was 0.274 ⫾ 0.095 g/mL, in those
in the AIOL arm it was 0.088 ⫾ 0.013 g/mL, and in those in
the ANIOL arm it was 0.103 ⫾ 0.016 g/mL (P ⫽ 0.505). The
mean serum concentration of Z at V1 was 0.013 ⫾ 0.011
g/mL in the entire study group, 0.013 ⫾ 0.002 g/mL in the
AIOL arm, and 0.014 ⫾ 0.002 g/mL in the ANIOL arm (P ⫽
0.785).
MPOD. The mean MPOD at V1 averaged across the retina
(i.e., average of MPOD at 0.25°, 0.5°, 1°, and 1.75°) was 0.18 ⫾
0.12 in the entire study group, 0.18 ⫾ 0.12 in the AIOL arm,
and 0.17 ⫾ 0.12 in the ANIOL arm (P ⫽ 0.898). The mean
MPOD at V1 at 0.25° (i.e., peak value) was 0.29 ⫾ 0.16 in the
entire study group, 0.27 ⫾ 0.14 in the AIOL arm, and 0.28 ⫾
0.17 in the ANIOL arm (P ⫽ 0.870). The mean MPOD at V1 at
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TABLE 1. Foveal (0.25°) and Parafoveal (7°) Relative Radiance and Derived MPOD before and after Cataract Surgery in Subjects with the AIOL
or the ANIOL Lens Implant
Subject
AIOL
2
5
7
11
12
14
16
18
21
24
27
29
31
32
33
34
42
Mean
SD
ANIOL
3
6
8
9
10
17
19
20
22
23
26
37
40
41
43
Mean
SD

V1 Mean F
Radiance

V1 Mean PF
Radiance

V2 Mean F
Radiance

V2 Mean PF
Radiance

MPOD at
0.25 V1

MPOD at
0.25 V2

MPOD
Change

1432
1778
1624
1179
1629
2180
1741
1295
2121
1199
1736
1276
1392
1364
1162
1408
1204
1513
316

1145
853
1174
1095
1482
1323
1261
879
1571
462
1350
899
787
1027
915
974
817
1060
282

1082
1475
1433
909
1114
1641
1449
1191
1215
1158
1276
1277
1411
979
1047
939
984
1211
214

840
617
1095
730
1047
830
796
839
648
474
829
993
712
759
831
709
630
787
159

0.18
0.59
0.28
0.06
0.09
0.55
0.30
0.28
0.36
0.62
0.24
0.26
0.42
0.22
0.17
0.28
0.27
0.30
0.16

0.18
0.62
0.22
0.14
0.05
0.54
0.46
0.25
0.43
0.60
0.31
0.21
0.47
0.17
0.16
0.18
0.29
0.31
0.18

0
⫺0.03
0.06
⫺0.08
0.04
0.01
⫺0.16
0.03
⫺0.07
0.02
⫺0.07
0.05
⫺0.05
0.05
0.01
0.1
⫺0.02
⫺0.01
0.06

2288
1858
1689
2216
1455
1181
1819
1183
1526
1492
1960
1432
1785
1577
1965
1695
333

1576
1199
1415
2068
1199
773
740
1049
1259
1343
1467
1015
1272
1004
1560
1263
338

2143
1727
1488
1500
1355
1146
1651
1197
1274
1331
2122
1431
1770
1569
1505
1547
298

1383
1089
1185
1388
1161
761
881
1060
1043
1188
1314
980
1329
971
1129
1124
183

0.48
0.40
0.17
0.11
0.16
0.30
0.72
0.09
0.17
0.09
0.31
0.27
0.32
0.37
0.26
0.28
0.17

0.49
0.41
0.19
0.07
0.12
0.28
0.50
0.09
0.15
0.09
0.52
0.29
0.27
0.39
0.24
0.27
0.16

⫺0.01
⫺0.01
⫺0.02
0.04
0.04
0.02
0.22
0
0.02
0
⫺0.21
⫺0.02
0.05
⫺0.02
0.02
0.01
0.08

0.5° was 0.23 ⫾ 0.15 for the entire study group, 0.24 ⫾ 0.15 in
the AIOL arm, and 0.21 ⫾ 0.15 in the ANIOL arm. (P ⫽ 0.643).

1263 ⫾ 338 [PFV1] and 1124 ⫾ 183 [PFV2], paired samples
t-test, P ⫽ 0.02) (Table 1).

MPOD 1 Week before (V1) and 1 Week after (V2)
Cataract Surgery

MPOD Alterations for AIOL and ANIOL Groups
over the Study Period: V1–V5

The mean relative radiance units obtained for 0.25° (fovea,
F) and 7° (parafovea, PF), along with MPOD for 0.25°, and
the change in MPOD between V1 and V2 are presented in
Table 1. The data show that MPOD recorded 1 week after
cataract surgery was unchanged when compared with readings taken 1 week before surgery in eyes with an AIOL
implant (mean MPOD at 0.25°, 0.30 ⫾ 0.16 and 0.31 ⫾ 0.18,
for V1 and V2, respectively; mean difference, ⫺0.01 ⫾ 0.06;
paired samples t-test, P ⫽ 0.631) and in eyes with an ANIOL
implant (mean MPOD at 0.25°, 0.28 ⫾ 0.17 and 0.27 ⫾ 0.16,
for V1 and V2, respectively; mean difference, 0.01 ⫾ 0.08;
paired samples t-test, P ⫽ 0.719). In contrast, the F and PF
values used in the derivation of MPOD were significantly
lower after cataract surgery in those with an AIOL implant
(mean ⫾ SD F and PF radiance units, 1513 ⫾ 316 [FV1] and
1211 ⫾ 214 [FV2], paired samples t-test, P ⫽ 0.000; and
1060 ⫾ 282 [PFV1] and 787 ⫾ 159 [PFV2], paired samples
t-test, P ⫽ 0.000) and in those with an ANIOL implant
(mean ⫾ SD F and PF radiance units ⫽ 1695 ⫾ 333 [FV1]
and 1527 ⫾ 298 [FV2], paired samples t-test, P ⫽ 0.017, and

We conducted a repeated-measures analysis of average MPOD
across the retina, measured at each of five study visits using a
general linear model approach, with lens as a between-patients
factor. This resulted in a statistically significant time/lens interaction effect, which remained significant (P ⬍ 0.05) using any
of the standard corrections for violation of sphericity. It is clear
from the means plots in Figure 1 and MPOD values presented
in Table 2, how this significant time–lens interaction effect
arises: MPOD increased with time (at least for some patients) in
the ANIOL group, but remained virtually static in the AIOL
group.
As the AIOL and ANIOL groups differ significantly with
respect to BMI, we conducted further repeated measures analyses with BMI included as a covariate. When comparing average MPOD differences between visits 2 and 5 (i.e., comparing
average MPOD immediately after surgery and 12 months later),
we obtained P ⫽ 0.008 for the time–IOL type interaction,
controlling for BMI. Including all five time points in the analysis, however, the time–IOL type interaction was no longer
significant (e.g., P ⫽ 0.108, with Huynh-Feldt correction for
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TABLE 3. Difference in Average MPOD between Visits 2 and 5, at
Each Degree of Retinal Eccentricity, in Subjects with the AIOL or
the ANIOL Lens Implant
AIOL
MPOD
Mean Difference
Eccentricity
(V5 ⴚ V2)
0.25
0.5
1
1.75

0.002
⫺0.017
⫺0.008
⫺0.0045

ANIOL

P

Mean Difference
(V5 ⴚ V2)

P

0.898
0.393
0.167
0.703

0.16
0.123
0.088
0.035

0.02
0.02
0.067
0.289

V5 ⫺ V2, change in macular pigment between visits 2 and 5;
MPOD eccentricity, the eccentricity at which MPOD was measured; P,
significance at P ⱕ 0.05 (paired-sample t-test).

FIGURE 1. Mean MPOD across the retina, at all study visits, in patients
in the AIOL and ANIOL groups. Mean MPOD measured at 0.25°, 0.5°,
1.0°, and 1.75° of retinal eccentricity. Standard error bars are included
at each time point for both the AIOL and ANIOL groups.

sphericity). Of note, the time–BMI interaction effect was also
not significant, indicating that differences in BMI between the
AIOL and ANIOL groups remained stable over time. The sensible conclusion to draw from our results therefore appears to
be that there is no need to control for BMI differences between
the two IOL groups.
Of interest, seven subjects (six in the ANIOL group and one
in the AIOL group) showed an increase of 0.08 units or more

in average MPOD between visits two and five. Comparing this
group of seven with the remaining subjects, we found no
significant differences in mean BMI (V1), serum L (V1) serum Z
(V1), diet score (V1), or age (V1). Distribution of iris color or
sex was also not significantly different (P ⬎ 0.05, for all tests).
It appears therefore that the observed changes in average
MPOD cannot be ascribed to any of these factors.
We also report some results (difference between V5 and V2
[final 12-month study visit minus time of lens implant]) for
MPOD measured at each degree of retinal eccentricity (0.25°,
0.5°, 1.0°, and 1.75°) in both the AIOL and ANIOL groups
(Table 3). It is clear from this table that the significant increases
in MPOD over the study period in the ANIOL group arose
primarily at the center (0.25° and 0.5°) of the fovea.

TABLE 2. Average MPOD at Each Study Visit in Subjects with the AIOL or the ANIOL Lens Implant and Differences in MPOD between Selected
Study Visits
Subject
AIOL
2
5
7
11
12
14
16
18
21
27
29
32
34
Mean
SD
ANIOL
3
6
8
9
10
17
19
20
22
26
40
Mean
SD

V1

V2

V3

V4

V5

V3 ⴚ V2

V4 ⴚ V2

V5 ⴚ V2

0.09
0.4
0.3
0.03
0.05
0.43
0.21
0.18
0.33
0.14
0.16
0.12
0.15
0.20
0.13

0.07
0.45
0.17
0.07
0.01
0.38
0.27
0.13
0.28
0.13
0.1
0.13
0.13
0.18
0.13

0.11
0.38
0.14
0.06
0
0.38
0.29
0.19
0.3
0.09
0.07
0.12
0.15
0.18
0.12

0.07
0.43
0.11
0.02
0.01
0.42
0.32
0.19
0.27
0.09
0.15
0.12
0.13
0.18
0.14

0.07
0.4
0.12
0.03
0
0.37
0.26
0.25
0.27
0.11
0.12
0.16
0.12
0.18
0.12

0.04
⫺0.07
⫺0.03
⫺0.01
⫺0.01
0
0.02
0.06
0.02
⫺0.04
⫺0.03
⫺0.01
0.02
0.00
0.04

0
⫺0.02
⫺0.06
⫺0.05
0
0.04
0.05
0.06
⫺0.01
⫺0.04
0.05
⫺0.01
0
0.00
0.04

0
⫺0.05
⫺0.05
⫺0.04
⫺0.01
⫺0.01
⫺0.01
0.12
⫺0.01
⫺0.02
0.02
0.03
⫺0.01
0.00
0.04

0.28
0.36
0.09
0.03
0.12
0.22
0.37
0.04
0.12
0.13
0.17
0.18
0.12

0.29
0.21
0.12
0.02
0.1
0.25
0.43
0.06
0.17
0.32
0.11
0.19
0.12

0.3
0.32
0.3
0.01
0.07
0.28
0.28
0.07
0.26
0.44
0.08
0.22
0.14

0.36
0.34
0.43
0.01
0.07
0.17
0.38
0.15
0.36
0.58
0.08
0.27
0.18

0.39
0.34
0.45
0
0.06
0.25
0.52
0.08
0.47
0.54
0.11
0.29
0.20

0.01
0.11
0.18
⫺0.01
⫺0.03
0.03
⫺0.15
0.01
0.09
0.12
⫺0.03
0.03
0.09

0.07
0.13
0.31
⫺0.01
⫺0.03
⫺0.08
⫺0.05
0.09
0.19
0.26
⫺0.03
0.08
0.13

0.1
0.13
0.33
⫺0.02
⫺0.04
0
0.09
0.02
0.3
0.22
0
0.10
0.13

V3 ⫺ V2 ⫽ change in MPOD between visit 2 and visit 3 (AIOL: P ⫽ 0.964; ANIOL: P ⫽ 0.392)
V4 ⫺ V2 ⫽ change in MPOD between visit 2 and visit 4 (AIOL: P ⫽ 1.000; ANIOL: P ⫽ 0.050)
V5 ⫺ V2 ⫽ change in MPOD between visit 2 and visit 5 (AIOL: P ⫽ 0.474; ANIOL: P ⫽ 0.028)
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all tests). Similar improvements in acuity were thus observed in
the AIOL and ANIOL groups over the time course of the study.

DISCUSSION

FIGURE 2. Mean serum concentrations of L, at all study visits, in
patients in the AIOL and ANIOL groups. Mean serum L is the mean
concentration of L at each study visit. Standard error bars are included
at each time point for both the AIOL and ANIOL groups.

Serum L and Z Concentrations for AIOL and
ANIOL Groups over the Study Period: V1–V5
No significant serum L effects were observed over the study
period (Fig. 2). There was a significant time effect for serum Z
over the study period (repeated-measures, general linear
model, e.g., using Huynh-Feldt correction for sphericity, P ⫽
0.038), but not a significant time–IOL interaction (P ⬎ 0.05 for
all tests) (Fig. 3). Thus, serum Z was significantly different at
different time points, but this was true in both the AIOL and
ANIOL groups.

Visual Acuity
Visual acuity was assessed using a Bailey-Lovie distance chart
and recorded with logMAR notation. For statistical analysis,
logMAR acuity was converted to a visual acuity rating (VAR)
notation. LogMAR 0 acuity (equivalent to 20/20 Snellen acuity)
was assigned a score of 100. Acuity was calculated on the basis
of every letter that was correctly identified above or below this
line, with each letter worth one mark, and each line therefore,
five marks. For example, a subject with corrected logMAR
acuity of 0.3 (Snellen equivalent 20/40), was assigned a mark of
85 [100 ⫺ 15 (3 lines ⫽ 15 marks)]. If the subject could
correctly identify two additional letters on the smaller logMAR
0.2 line, they were assigned a score of 87.
The mean BCVAR for the entire study group at V1 was
82.49 ⫾ 7.68. There was a predictable and statistically significant improvement in acuity after cataract surgery and postoperative BCVAR at V2 for the entire study group was 89.69 ⫾
6.79 (paired samples t-test; t ⫽ ⫺4.703, P ⬍ 0.001). The
improvement in acuity was maintained throughout the study
period, and BCVAR for the entire study group at V5 was
91.84 ⫾ 5.20.
Visual acuity results were further analyzed to assess the
impact of lens type on visual outcome. The mean BCVAR at V1
was 82.57 ⫾ 8.37 for the AIOL group, and 82.39 ⫾ 7.02 for the
ANIOL group. Postoperative BCVAR at V2 was 89.72 ⫾ 6.57 for
the AIOL group and 89.64 ⫾ 7.32 for the ANIOL group. Final
BCVAR at V5 was 91.93 ⫾ 6.16 for the AIOL group and 91.73 ⫾
4.18 for the ANIOL group. Statistical analysis confirms a significant time effect on BCVAR (repeated-measures, general linear
model, e.g., using Huynh-Feldt correction for sphericity P ⬍
0.001), but not a significant time–lens interaction (P ⬎ 0.05 for

This study was designed to measure and compare the effect of
cataract surgery on MPOD over a 1-year period in eyes in
which a standard UV-light filtering intraocular lens (AIOL) was
implanted and in eyes in which a blue-light and UV-light filtering intraocular lens (ANIOL) was implanted. Forty-two patients
scheduled for cataract surgery at WRH were randomized to
have either an AIOL or an ANIOL implanted during surgery (in
place of the cataractous lens). MPOD was measured at baseline
(1 week before and 1 week after cataract surgery) and at 3, 6,
and 12 months after surgery in all patients. Serum carotenoid
concentrations were also measured at each study visit in all
patients to control for any potentially confounding variables
relating to their MPOD measurements. This study was prospective, randomized, controlled, double-blind in design, and, to
our knowledge, it is the first of its kind.
Blue light has been implicated in the development and
progression of AMD after cataract surgery.4,5,22,40 – 44 Indeed,
after cataract surgery, the retina is exposed to more blue light
than at any stage in the patient’s lifetime,41 and Wang et al.
reported a 5-year, two- to fivefold increased risk of development of late-stage AMD after cataract surgery in individuals
without AMD at baseline.22 Furthermore, in vitro, both RPE
cell apoptosis and upregulation of vascular endothelial growth
factor (VEGF), one of the most potent proangiogenic factors in
the pathogenesis of neovascular AMD, have been demonstrated in A2E-laden RPE cells on exposure to light,40,42 but
these effects are relatively attenuated when the light is filtered
through a blue-light filtering IOL.43,44 Of interest, the human
crystalline lens yellows with age, and transmits less blue light
than a younger crystalline lens.24 The transmission of blue light
is further reduced with cataract formation, and this may confer
some degree of protection against AMD at a stage in life when
the concentration of RPE lipofuscin (the major chromophore
in this line of cells) peaks at the macula.45 If indeed cataract
surgery is an independent risk factor for development or progression of AMD, replacement of the natural (blue light filtering) crystalline lens with a clear (non– blue light filtering)
artificial IOL may contribute to any observed increase in risk
for progression or development of AMD after cataract surgery.

FIGURE 3. Mean serum concentrations of Z, at all study visits, in
patients in the AIOL and ANIOL groups. Mean serum Z is the mean
concentration of Z at each study visit. Standard error bars are included
at each time point for both the AIOL and ANIOL groups.
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Alcon has been producing a blue-light–filtering intraocular
lens (ANIOL) since 2000, with a view to attenuating any increased risk of progression or development of AMD after cataract surgery. The ANIOL was the first blue-light–filtering IOL
on the market in North America,46 and was designed to mimic
the transmittance characteristics of the adult human crystalline
lens, with the absorption characteristics of a 20-D ANIOL being
similar to that of a 53-year-old crystalline lens.47 The ANIOL is
entirely similar to the AIOL apart from a covalently bound
chromophore that partially absorbs light in the 400- to 500-nm
spectral range. Conventional UV-blocking IOLs (such as the
AIOL) display a sharp increase in light transmission beyond 400
nm, whereas the ANIOL allows only a 10% transmittance at 406
nm increasing to a 50% transmittance at 459 nm, and an 80%
transmittance at 500 nm,23 thus blocking transmission of a
large proportion of high-energy and potentially injurious shortwavelength light. Despite the greatly reduced transmission of
short-wavelength (blue) light, visual acuity, color perception,
and contrast sensitivity have repeatedly been found to be
equivalent under photopic and mesopic conditions with the
UV-only blocking AIOL and the ANIOL.48 –59 The acuity results
reported herein are in general agreement with those in previous studies and provide further evidence that lens type,
whether ANIOL or AIOL, has little impact on postoperative
photopic, high-contrast visual acuity. Reduced scotopic sensitivity has been demonstrated in some studies with the
ANIOL47,60,61; however, this has generally been accepted to be
of little visual or functional significance61– 65 and does not
affect patients’ quality of life.66
In this study, we set out to evaluate the effect of implantation of a blue-light filtering IOL on MPOD and to compare the
findings with control subjects in whom a non– blue-light–filtering IOL was implanted. Given the growing, but inconclusive,
evidence base for a protective role of MP in AMD (recently
reviewed by Loane et al.67), the results of this study indicate
that implantation of an ANIOL at the time of cataract surgery
may confer protection against progression or development of
AMD. We postulated that reducing the amount of blue light
incident on the retina (by implantation of an ANIOL as opposed to an AIOL) would lead to less generation of free radicals
in response to irradiation with short-wavelength (blue) light.68
As a consequence, in theory at least, depletion of MP over time
(caused by neutralizing free radicals) would be attenuated in
those eyes with an ANIOL implant compared with those with
an AIOL implant.
MPOD measured 1 week after surgery was unchanged compared with readings taken 1 week before surgery in each study
group (although foveal and parafoveal radiances were reduced
after surgery as expected, but the relative radiance remained
consistent). The ANIOL more closely approximates the transmittance characteristics of the natural crystalline lens and, as
such, reduced radiances were more evident in the AIOL group.
The stability of MPOD measured before and after surgery demonstrates that the measurement of MPOD using HFP is not
influenced artifactually or otherwise by the event of cataract
surgery (whether an AIOL or an ANIOL is implanted), and this
stability therefore lends validity to MPOD measurements taken
at 3, 6, and 12 months after surgery. These findings are consistent with those of Ciulla et al.,69 who also found no significant change in MPOD measurements taken immediately before
and after cataract surgery in a patient population with inclusion and exclusion criteria similar to those in our study (with
no patients in their study having any evidence of macular
disease and a median best corrected Snellen distance visual
acuity before surgery of 20/50).
We found that MPOD remained stable over the course of
the study in the group with an AIOL implant. However, and in
contrast, in eyes in which an ANIOL was implanted, MPOD
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increased over the duration of the study period, with a statistically significant increase in MPOD at months 3, 6, and 12 after
surgery. Of note, dietary levels and serum concentrations of L
and Z remained largely unchanged over the course of the
study. Nolan et al.70 have demonstrated serial month-to-month
consistency of MPOD measurements using HFP over a 24month period in healthy subjects in whom serum concentrations of the macular carotenoids were stable, consistent with
the findings of Wenzel et al.71 (investigating MPOD in two male
subjects over a 20-day period), who reported that the optical
density of the macular carotenoids is unaffected by diurnal
variations in exposure to ambient levels of light. Of note,
Wenzel et al. and Nolan et al.70 were uncontrolled observational studies. In other words, the stability of MPOD appears to
be unaffected (in the context of a stable diet) over long periods, which renders our findings all the more interesting, given
that we have (in the context of a randomized controlled trial)
demonstrated that differential filtration of blue light after cataract surgery influences MPOD with the passage of time.70,71
Our findings prompt a discussion on the relationship, if any,
between MPOD and age, as the yellowing of the crystalline lens
with age results in an age-related increase in prereceptoral
filtration of blue light. This phenomenon, given our finding
that blue-filtering IOLs result in augmentation of MPOD, in
theory at least, might be expected to give rise to an age-related
increase in MPOD. However, most studies do not support such
an association, perhaps reflecting the known age-related increase in oxidant load, which may offset any protective effect
of prereceptorial filtration of blue light.3
Our initial hypothesis postulated a reduction in MPOD with
implantation of an AIOL (due to the increased transmittance of
short-wavelength blue light) and relative stabilization of MPOD
with ANIOL implantation and, as such, our findings were
somewhat unexpected. The MPOD in those eyes with the
AIOL implant remained constant over the one-year study period, despite the fact that blue-light transmission with the AIOL
implant is greater than that in a 71-year-old (mean age of
patients in the AIOL group) cataractous lens. Indeed, a 74-yearold (mean age of patients in the ANIOL group) cataractous lens
may also be expected to transmit less blue light than the
ANIOL. However, in eyes with an ANIOL implant, MPOD
increased over the 1-year follow-up period in our study. It is
difficult to explain our findings, although it is possible that
increased visible light irradiation of the retina after cataract
surgery stimulates enhanced retinal capture of circulating L
and Z in an attempt to offset a possible increase in photooxidative retinal injury, but that the heralded increase in photooxidative retinal injury does not occur in eyes with a bluefiltering IOL implant. Also, it is possible that there is some
degree of autoregulation of MPOD in the context of a stable
diet and that such autoregulation is disturbed by cataract surgery as a result of increased light incident on the macula and a
consequential depletion of existing MP (because of increased
photochemical oxidant load). However, the presence of a
blue-filtering IOL attenuates the amount of blue light incident
on the retina, with perhaps a parallel reduction in the extent of
depletion of macular carotenoids (because of reduced photochemical injury), with a consequential rise in MPOD.
In conclusion, this study provides evidence that implanting
an IOL that filters blue light (ANIOL) results in augmentation of
MPOD. The importance of this finding rests on the fact that any
benefits associated with augmentation of MPOD, in terms of
AMD prevention or progression (yet to be proven), will be
conferred on patients with an ANIOL implant at the time of
cataract surgery, and may be of particular importance in the
modern era when IOL implantation often occurs at an earlier
stage in a patient’s lifetime (such as in pediatric cataract surgery, refractive lens exchange and relatively early lens opacity
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in patients with a long postoperative life expectancy). However, further study is required in the form of controlled longterm trials to investigate whether implantation of a blue-light
filtering IOL is effective in preventing or delaying development
or progression of AMD.
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